NCT06793215 - A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

October 31, 2030

Conditions

Non-Small Cell Lung CancerKRAS G12C Lung Cancer

Interventions

DRUG

Divarasib

Divarasib will be administered orally QD

DRUG

Pembrolizumab

Pembrolizumab will be administered via IV infusion Q3W

DRUG

Pemetrexed

Pemetrexed will be administered via IV infusion Q3W

DRUG

Carboplatin

Carboplatin will be administered via IV infusion Q3W

DRUG

Cisplatin

Cisplatin will be administered via IV infusion Q3W

Trial Locations (10)

112

RECRUITING

Taipei Veterans General Hospital, Taipei

31405

RECRUITING

Summit Cancer Care PC, Savannah

33013

RECRUITING

BioResearch Partner, Hialeah

40201

RECRUITING

Chung Shan Medical University Hospital, Taichung

48334

RECRUITING

Profound Research, LLC, Farmington Hills

60521

RECRUITING

Hope and Healing Cancer Services, Hinsdale

75708

RECRUITING

University of Texas Health Center at Tyler, Tyler

80756

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

99508

RECRUITING

Alaska Oncology and Hematology, Anchorage

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong